IDEAYA grants CCO 155,000 stock options

IDEAYA Biosciences, Inc. granted a new equity award to its Chief Commercial Officer, Stuart Dorman.

Rhea-AI Filing Summary

IDEAYA Biosciences, Inc. granted a new equity award to its Chief Commercial Officer, Stuart Dorman. On January 30, 2026, he received a stock option for 155,000 shares of common stock with an exercise price of $32.19 per share.

According to the vesting schedule, 25% of the option vests on the first anniversary of January 1, 2026, and the remaining shares vest in equal monthly installments over the following three years, so the option becomes fully vested and exercisable on the fourth anniversary of the vesting commencement date.

Insider Trade Summary

Grant/Award: 155,000 shares

Grant/Award 1 txn

Insider DORMAN STUART

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	155,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 155,000 contracts (Direct)

Footnotes (1)

1. F1. 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did IDEAYA Biosciences (IDYA) report for Stuart Dorman?

IDEAYA Biosciences (IDYA) reported a grant of stock options to Chief Commercial Officer Stuart Dorman. He received options to purchase 155,000 shares of common stock at an exercise price of $32.19 per share, reflecting a standard equity incentive award structure.

What is the size and exercise price of the new IDEAYA (IDYA) stock option grant?

The new IDEAYA (IDYA) stock option grant to Chief Commercial Officer Stuart Dorman covers 155,000 shares of common stock. The option has a fixed exercise price of $32.19 per share, meaning he must pay that amount per share to purchase the stock once vested.

How do the IDEAYA (IDYA) options granted to Stuart Dorman vest over time?

The IDEAYA (IDYA) options granted to Stuart Dorman vest over four years. Twenty-five percent vest on the first anniversary of January 1, 2026, and the remaining shares vest in equal monthly installments thereafter until fully vested on the fourth anniversary.

When will Stuart Dorman’s IDEAYA (IDYA) stock options be fully exercisable?

Stuart Dorman’s IDEAYA (IDYA) stock options become fully exercisable on the fourth anniversary of the January 1, 2026 vesting commencement date. The award uses a one-year cliff for 25% of the shares followed by monthly vesting for the remaining portion over three additional years.

What role does Stuart Dorman hold at IDEAYA Biosciences (IDYA) in this Form 4 filing?

In this Form 4, Stuart Dorman is identified as an officer of IDEAYA Biosciences (IDYA), serving as Chief Commercial Officer. The filing reports his receipt of a stock option award as part of his compensation, with vesting tied to continued service over four years.

Is the IDEAYA (IDYA) stock option grant to Stuart Dorman a direct holding?

Yes, the IDEAYA (IDYA) stock option grant to Stuart Dorman is reported as a direct holding. After the transaction, he beneficially owns 155,000 derivative securities in the form of stock options, subject to the four-year vesting schedule described in the filing’s footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/02/2026 - 08:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DORMAN STUART

(Last) (First) (Middle)

C/O IDEAYA BIOSCIENCES, INC.

5000 SHORELINE COURT, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IDEAYA Biosciences, Inc. [ IDYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$32.19	01/30/2026		A		155,000		(1)	01/30/2036	Common Stock	155,000	$0	155,000	D

Explanation of Responses:

1. 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

	/s/ Joshua Bleharski, as Attorney-in-Fact for Stuart Dorman	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.